Samsung Biologics makes $1.8 billion all-cash offer for Switzerland's PolyPeptide Group
South Korea's Samsung Biologics announced an all-cash bid of 1.46 billion Swiss francs ($1.8 billion) for Switzerland's PolyPeptide Group. The deal is seen as a move to expand Samsung's pharmaceutical manufacturing supply chain.
Samsung Biologics said Monday it had made an all-cash bid of 1.46 billion Swiss francs (roughly $1.8 billion) for Swiss peptide manufacturer PolyPeptide Group, as part of the South Korean company's push to expand its contract drug manufacturing business.
If completed, the deal would significantly expand Samsung's peptide-based drug manufacturing capacity and strengthen its production footprint in Europe. Markets read the move as part of Samsung's broader effort to build competitive scale in pharmaceutical manufacturing.
PolyPeptide shares rose following the announcement. Analysts noted the deal remains subject to regulatory approval, with the process expected to become clearer over the coming months.
Read next
JPMorgan's Jamie Dimon says markets underestimate risks, wouldn't buy stocks or Treasurys now
JPMorgan Chase CEO Jamie Dimon said financial markets are underestimating current geopolitical and economic risks. Dimon told an audience he personally would not buy stocks or US Treasurys at today's prices.
TSMC accelerates Arizona factory buildout on AI chip demand
Wall St Ends Day and Week Lower as Chip Sell-Off Broadens
Alphabet, Intel Earnings Take Center Stage for AI Trade This Week
